Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN versus MYHIBBIN.
GRISEOFULVIN vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubular protein tubulin, disrupting mitotic spindle formation and inhibiting fungal cell mitosis. Also interferes with fungal nucleic acid synthesis and cell wall deposition.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
500 mg orally once daily or 250 mg orally twice daily; microsize formulation: 500-1000 mg orally once daily; ultramicrosize formulation: 330-375 mg orally once daily. Administer with fatty meal to enhance absorption.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Clinical Note
moderateGriseofulvin + Estrone sulfate
"The metabolism of Estrone sulfate can be increased when combined with Griseofulvin."
Clinical Note
moderateGriseofulvin + Tranilast
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast."
Clinical Note
moderateGriseofulvin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic acid."
Clinical Note
moderateGriseofulvin + Nimesulide
Terminal elimination half-life is 9 to 24 hours; clinically, it allows once or twice daily dosing.
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; metabolites excreted in urine (approximately 50%) and feces (approximately 36%) within 24 hours.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category D/X
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide."